Pacific Edge posts $14.5m loss as it awaits US Medicare decisions

Pacific Edge posts $14.5m loss as it awaits US Medicare decisions
Pacific Edge chief executive Peter Meintjes says as each day passes, he feels more confident about a favourable decision from Novitas. (Image: Supplied)
John Anthony
Dunedin-headquartered cancer diagnostics company Pacific Edge has posted a $14.5 million after-tax loss for the six months to September 30.The NZX and ASX-listed company said it was awaiting outcomes of several events that had the potential to renew growth in Cxbladder, its urine-based genomic biomarker test for the detection and surveillance of bladder cancer. The events include:Novitas, the Medicare Administrative Contractor (MAC) with responsibility for Pacific Edge’s US lab, making a favourable policy decision on a Local Coverage...

More Markets

Infratil lifts market after ASX 200 inclusion
Markets Market close

Infratil lifts market after ASX 200 inclusion

Spark is making a steady comeback.

Infratil to join ASX 200, shares up 4%
Infrastructure

Infratil to join ASX 200, shares up 4%

Analysts expect the liquidity boost to help Infratil's growth.

Forsyth Barr sets Tower target price at 25.8% premium
Markets

Forsyth Barr sets Tower target price at 25.8% premium

Tower has graduated out of having to pay for Forsyth Barr coverage.